Ovarian Cancer - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
- Defining Therapy for Recurrent Platinum-sensitive Ovarian Cancer
(Posted: 06/10/2008) - In this phase III clinical trial, women with platinum-sensitive, recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer will be randomly assigned to undergo secondary cytoreductive surgery, if they are candidates for such surgery, and then randomly assigned to chemotherapy with or without bevacizumab. Women who aren't surgical candidates will be randomized to chemotherapy with or without bevacizumab.
- New Drug Combination for Ovarian and Primary Peritoneal Cancers
(Posted: 12/04/2007) - Women with ovarian epithelial or primary peritoneal cancer whose disease has relapsed less than 6 months after treatment with initial chemotherapy will receive cisplatin and a second drug called flavopiridol in this phase II clinical trial.
- Zoledronate to Preserve Bone Mineral Density
(Posted: 02/27/2007) - Women undergoing risk-reducing surgical removal of their ovaries will have their bone mineral density checked prior to surgery and will receive calcium and vitamin D supplements for 18 months following surgery. Half of the women will be randomly assigned to receive intravenous zoledronate once every 6 months, while the rest will be monitored without receiving additional treatment.
- Gene Therapy for Metastatic Cancer
(Posted: 11/21/2006) - In the trial, researchers will harvest normal T lymphocytes from patients' blood and modify these immune system cells to recognize p53 protein, a common hallmark of many cancers. The modified cells will be enriched in the laboratory and then infused back into the patients.
- Targeted Combination Therapy for Advanced Solid Tumors
(Posted: 07/19/2005) - In this study, researchers are assessing the safety and combined effectiveness of bevacizumab and a second drug called sorafenib. Both bevacizumab and sorafenib inhibit the formation of blood vessels to tumors and may act synergistically when combined.